Stockscreener 앱 받기
7.10
0.85%
0.06
시간 외 거래:
7.10
전일 마감가:
$7.04
열려 있는:
$7
하루 거래량:
104.00K
Relative Volume:
0.40
시가총액:
$183.20M
수익:
$34.26M
순이익/손실:
$-46.61M
주가수익비율:
-1.3705
EPS:
-5.1806
순현금흐름:
$-62.01M
1주 성능:
-4.57%
1개월 성능:
+17.94%
6개월 성능:
-14.35%
1년 성능:
+38.94%
1일 변동 폭
$6.945
$7.24
1주일 범위
$6.94
$7.975
52주 변동 폭
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
명칭
Precision Biosciences Inc
전화
919-314-5512
주소
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
7.10 | 181.65M | 34.26M | -46.61M | -62.01M | -5.1806 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | 개시 | Guggenheim | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-06-09 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 재개 | BTIG Research | Buy |
| 2020-04-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-05 | 개시 | Stifel | Buy |
| 2020-02-25 | 개시 | William Blair | Outperform |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | H.C. Wainwright | Buy |
| 2019-04-22 | 개시 | Barclays | Overweight |
| 2019-04-22 | 개시 | Goldman | Buy |
| 2019-04-22 | 개시 | JP Morgan | Overweight |
| 2019-04-22 | 개시 | Jefferies | Buy |
모두보기
Precision Biosciences Inc 주식(DTIL)의 최신 뉴스
Precision BioSciences (DTIL) Presents Promising Data on PBGENE-D - GuruFocus
Gene-editing trial update points to fewer crises in 7 infants - Stock Titan
Precision BioSciences to present DMD gene therapy data at May conference - Investing.com
New Duchenne data backing earlier treatment gets ASGCT oral slot - Stock Titan
Should you buy Precision BioSciences (DTIL) after golden cross? - MSN
Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4) - marketscreener.com
Precision BioSciences (DTIL) surpasses Q4 earnings and revenue estimates - MSN
Precision BioSciences announces grant of inducement awards - TipRanks
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
Precision BioSciences (DTIL) Grants Inducement Award to New Empl - GuruFocus
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 - Business Wire
Empery Asset Management, LP Reduces Stake in Precision BioSciences Inc - GuruFocus
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Precision BioSciences stock (US74019P1084): Is its gene-editing platform strong enough to unlock bio - AD HOC NEWS
Precision BioSciences reports encouraging muscle improvements in preclinical DMD gene therapy study - MSN
Precision BioSciences stock (US74019P1084): Is its gene editing platform strong enough to unlock bio - AD HOC NEWS
DTIL Assumed by Jones Trading -- Price Target Announced at $30 - GuruFocus
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Decreases By 16.2% - MarketBeat
JonesTrading Reiterates Buy Rating for Precision BioSciences (NASDAQ:DTIL) - MarketBeat
JonesTrading Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Jones Trading initiates Precision BioSciences stock coverage with buy rating - Investing.com UK
Jones Trading initiates Precision BioSciences stock coverage with buy rating By Investing.com - Investing.com South Africa
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences - European AIDS Treatment Group
Precision BioSciences Expands ELIMINATE-B Trial to Europe - National Today
Precision BioSciences (DTIL) Expands Hepatitis B Trial to Europe - GuruFocus
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries - BioSpace
Empery Asset Management, Ryan M. Lane (DTIL) disclose 7.63% ownership - Stock Titan
Precision BioSciences Expands Eliminate-B Trial for Pbgene-Hbv In France And Romania - marketscreener.com
Should You Buy Precision BioSciences (DTIL) After Golden Cross? - Yahoo Finance
DTIL Options Volatility — NASDAQ:DTIL - TradingView
DTIL Options Chain — NASDAQ:DTIL - TradingView
Jobs Data: How does Precision BioSciences Inc compare to its peersStock Surge & Verified High Yield Trade Plans - baoquankhu1.vn
How does Precision BioSciences Inc compare to its peersWeekly Market Summary & AI Forecasted Stock Moves - baoquankhu1.vn
DTIL Price Today: Precision BioSciences, Inc. Stock Price, Quote & Chart - MEXC
Precision BioSciences to Attend Healthcare Conference - National Today
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Precision BioSciences (NASDAQ: DTIL) details equity plan, charter change in 2026 proxy - Stock Titan
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Can PrecisionBio (DTIL) Stock Maintain Growth | Price at $6.14, Up 5.58%Pro Level Trade Signals - Xã Châu Thành
Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Precision Biosciences Inc (DTIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):